Edition:
India

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

10.60USD
17 Nov 2017
Change (% chg)

$-0.05 (-0.47%)
Prev Close
$10.65
Open
$10.50
Day's High
$10.77
Day's Low
$10.38
Volume
173,894
Avg. Vol
295,784
52-wk High
$29.95
52-wk Low
$8.68

Chart for

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated... (more)

Overall

Beta: 2.62
Market Cap(Mil.): $863.35
Shares Outstanding(Mil.): 67.71
Dividend: --
Yield (%): --

Financials

BRIEF-Alder Biopharmaceuticals Q3 loss per share $0.92

* Alder biopharmaceuticals announces third quarter 2017 financial and operating results

08 Nov 2017

BRIEF-Alder Biopharmaceuticals Q2 loss per share $1.48

* Alder Biopharmaceuticals announces second quarter 2017 financial and operating results

09 Aug 2017

BRIEF-Alder Biopharmaceuticals announces commencement of public offering of common stock

* Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock

12 Jul 2017

Alder's shares tumble as migraine drug data disappoints

Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectations, sending its shares plunging as much as 26 percent to a more than two-and-half year low.

27 Jun 2017

BRIEF-Alder Biopharmaceuticals announces positive eptinezumab phase 3 results

* Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine

27 Jun 2017

Alder's migraine drug meets main goal in late-stage study

June 27 Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.

27 Jun 2017

Earnings vs. Estimates